122 related articles for article (PubMed ID: 31839602)
1. Evaluation of the expression of P16INK4A by immunohistochemistry in post-neoadjuvant chemotherapy hormone receptor negative breast cancer specimens.
Febres-Aldana CA; Kuritzky N; Krishnamurthy K; Poppiti R; Howard L
Breast Dis; 2020; 39(2):51-59. PubMed ID: 31839602
[TBL] [Abstract][Full Text] [Related]
2. RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer.
Witkiewicz AK; Ertel A; McFalls J; Valsecchi ME; Schwartz G; Knudsen ES
Clin Cancer Res; 2012 Sep; 18(18):5110-22. PubMed ID: 22811582
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management?
Xian Z; Quinones AK; Tozbikian G; Zynger DL
Hum Pathol; 2017 Apr; 62():215-221. PubMed ID: 28041972
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
5. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy.
Barron AU; Hoskin TL; Day CN; Hwang ES; Kuerer HM; Boughey JC
JAMA Surg; 2018 Dec; 153(12):1120-1126. PubMed ID: 30193375
[TBL] [Abstract][Full Text] [Related]
6. Predictive Clinicopathologic and Dynamic Contrast-Enhanced MRI Findings for Tumor Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Eom HJ; Cha JH; Choi WJ; Chae EY; Shin HJ; Kim HH
AJR Am J Roentgenol; 2017 Jun; 208(6):W225-W230. PubMed ID: 28350486
[TBL] [Abstract][Full Text] [Related]
7. The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis.
Stover DG; Coloff JL; Barry WT; Brugge JS; Winer EP; Selfors LM
Clin Cancer Res; 2016 Dec; 22(24):6039-6050. PubMed ID: 27330058
[TBL] [Abstract][Full Text] [Related]
8. A three-marker signature identifies senescence in human breast cancer exposed to neoadjuvant chemotherapy.
El-Sadoni M; Shboul SA; Alhesa A; Shahin NA; Alsharaiah E; Ismail MA; Ababneh NA; Alotaibi MR; Azab B; Saleh T
Cancer Chemother Pharmacol; 2023 Apr; 91(4):345-360. PubMed ID: 36964435
[TBL] [Abstract][Full Text] [Related]
9. Correlations between molecular subtypes and pathologic response patterns of breast cancers after neoadjuvant chemotherapy.
Lee HJ; Song IH; Seo AN; Lim B; Kim JY; Lee JJ; Park IA; Shin J; Yu JH; Ahn JH; Gong G
Ann Surg Oncol; 2015 Feb; 22(2):392-400. PubMed ID: 25192679
[TBL] [Abstract][Full Text] [Related]
10. Stromal Clusterin Expression Predicts Therapeutic Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer.
Wang Y; Brodsky AS; Xiong J; Lopresti ML; Yang D; Resnick MB
Clin Breast Cancer; 2018 Jun; 18(3):e373-e379. PubMed ID: 28890185
[TBL] [Abstract][Full Text] [Related]
11. CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy.
Tokunaga E; Fujita A; Takizawa K; Baba K; Akiyoshi S; Nakamura Y; Ijichi H; Masuda T; Koga C; Tajiri W; Ohno S; Taguchi K; Ishida M
Breast Cancer; 2019 Jan; 26(1):47-57. PubMed ID: 29971631
[TBL] [Abstract][Full Text] [Related]
12. NOXA expression is downregulated in human breast cancer undergoing incomplete pathological response and senescence after neoadjuvant chemotherapy.
Al Shboul S; El-Sadoni M; Alhesa A; Abu Shahin N; Abuquteish D; Abu Al Karsaneh O; Alsharaiah E; Ismail MA; Tyutyunyk-Massey L; Alotaibi MR; Neely V; Harada H; Saleh T
Sci Rep; 2023 Sep; 13(1):15903. PubMed ID: 37741850
[TBL] [Abstract][Full Text] [Related]
13. Clinical Implications of Transcriptomic Changes After Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Orozco JIJ; Grumley JG; Matsuba C; Manughian-Peter AO; Chang SC; Chang G; Gago FE; Salomon MP; Marzese DM
Ann Surg Oncol; 2019 Oct; 26(10):3185-3193. PubMed ID: 31342395
[TBL] [Abstract][Full Text] [Related]
14. How Often Is Treatment Effect Identified in Axillary Nodes with a Pathologic Complete Response After Neoadjuvant Chemotherapy?
Barrio AV; Mamtani A; Edelweiss M; Eaton A; Stempel M; Murray MP; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3475-3480. PubMed ID: 27469123
[TBL] [Abstract][Full Text] [Related]
15. MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy.
Calhoun BC; Portier B; Wang Z; Minca EC; Budd GT; Lanigan C; Tubbs RR; Morrison LE
BMC Cancer; 2016 Aug; 16(1):695. PubMed ID: 27576528
[TBL] [Abstract][Full Text] [Related]
16. Diffusion-weighted imaging in assessing pathological response of tumor in breast cancer subtype to neoadjuvant chemotherapy.
Liu S; Ren R; Chen Z; Wang Y; Fan T; Li C; Zhang P
J Magn Reson Imaging; 2015 Sep; 42(3):779-87. PubMed ID: 25580585
[TBL] [Abstract][Full Text] [Related]
17. MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer.
Weber JJ; Jochelson MS; Eaton A; Zabor EC; Barrio AV; Gemignani ML; Pilewskie M; Van Zee KJ; Morrow M; El-Tamer M
J Am Coll Surg; 2017 Dec; 225(6):740-746. PubMed ID: 28919579
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
Fujita N; Enomoto Y; Inakami K; Yanagisawa T; Iguchi C; Aono T; Nomura T; Yamamoto H; Kasugai T; Shiba E
Oncology; 2020; 98(1):35-41. PubMed ID: 31574500
[TBL] [Abstract][Full Text] [Related]
19. Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer.
Goetz MP; Kalari KR; Suman VJ; Moyer AM; Yu J; Visscher DW; Dockter TJ; Vedell PT; Sinnwell JP; Tang X; Thompson KJ; McLaughlin SA; Moreno-Aspitia A; Copland JA; Northfelt DW; Gray RJ; Hunt K; Conners A; Sicotte H; Eckel-Passow JE; Kocher JP; Ingle JN; Ellingson MS; McDonough M; Wieben ED; Weinshilboum R; Wang L; Boughey JC
J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376176
[TBL] [Abstract][Full Text] [Related]
20. Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients.
Wang RX; Chen S; Huang L; Shao ZM
BMC Cancer; 2018 Sep; 18(1):909. PubMed ID: 30241470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]